Tokyo, Dec. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059842) titled 'TalPioneer - Japan: Panel Interview of ONcology practices with Emergent Experience of Talquetamab in the Real World (Japan)' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Relapsed or refractory multiple myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - 1.To characterize current talquetamab treatment strategies and administration practices, including patient profiles and treatment sequencing, as well as dosing schedules and dose modifications during the initial step-up phase and ongoing...